VANI - NASDAQ
Vivani Medical, Inc.
$1.28
+0.39%Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
At a Glance
Live SnapshotVivani Medical, Inc. Profit Bridge
Profitability Analysis
Vivani Medical, Inc. Income Statement
VANI • NASDAQ
| Vivani Medical, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.4M | 6.9M | 8M | 4M | 9M | 3.4M | 1.6M | 1.4M | |
GROSS PROFIT | ||||||||||||||
(424K) | (0.0) | (357K) | (0.0) | (0.0) | (0.0) | (2.2M) | (4.9M) | (7.8M) | (9.3M) | (4.3M) | (3.6M) | (5.6M) | (4.4M) | |
-424K | 0.0 | -357K | 0.0 | 0.0 | 0.0 | 1.2M | 2M | 211K | -5.4M | 4.6M | -160.3K | -4.1M | -3M | |
OPERATING INCOME | ||||||||||||||
(27.1M) | (24.7M) | (26.6M) | (21.2M) | (13.3M) | (9.2M) | (31.8M) | (36.8M) | (28.9M) | (27.8M) | (24.7M) | (21.1M) | (13.9M) | (13M) | |
(9.4M) | (8.9M) | (10M) | (5.4M) | (2.3M) | (2.4M) | (15.3M) | (26.6M) | (23.6M) | (21.8M) | (20.7M) | (13.4M) | (7.5M) | (6.2M) | |
(18.1M) | (15.7M) | (17M) | (14.2M) | (11M) | (6.9M) | (16.5M) | (10.2M) | (8M) | (5.3M) | (3M) | (5M) | (3.2M) | (3M) | |
-27.6M | -24.7M | -27M | -21.2M | -13.3M | -9.2M | -30.6M | -34.8M | -28.7M | -33.2M | -20M | -21.2M | -18M | -16M | |
PRE-TAX INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (29K) | (7M) | (5M) | (267K) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16K | 0.0 | 0.0 | 0.0 | 0.0 | -27K | -7M | -5M | -259.5K | |
-424K | (0.0) | -357K | (1.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (2.6M) | -727K | -991K | (2.6M) | (3.2M) | (3.7M) | |
947K | 1.2M | 1.3M | 7.4M | 550K | -36K | -3M | -269K | 193K | 31K | 29K | -14M | -5M | -257.7K | |
-26.6M | -23.5M | -25.7M | -13.9M | -12.8M | -9.3M | -33.6M | -35.1M | -28.5M | -33.2M | -20M | -35.2M | -23M | -16.3M | |
NET INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (86K) | (93K) | (31K) | (58K) | (0.0) | (42.2K) | (9.3K) | |
-26.6M | -23.5M | -25.7M | -13.9M | -12.8M | -9.3M | -33.6M | -35.1M | -28.5M | -33.2M | -20M | -35.2M | -23M | -16.3M |
SEC Filings
VANI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 27, 2026 | January 25, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 26, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 03, 2025 | October 03, 2025 | 2025 |
Related Guides
Continue your VANI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.